SCHEMBL19059588

SCHEMBL19059588

O=C(O)CCCC(=O)NCCC1COCCN1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ARG1 P05089 2/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
EPHX2 P34913 3/20 0.33
USP2 O75604 1/20 0.33
MALT1 Q9UDY8 1/20 0.32
ALDH1A1 P00352 1/20 0.32
PRCP P42785 1/20 0.32
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
KMT2A Q03164 1/20 0.32
SLC6A5 Q9Y345 1/20 0.32
HDAC3 O15379 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC10 Q969S8 1/20 0.31
HDAC11 Q96DB2 1/20 0.31
HDAC8 Q9BY41 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22409372 0.81 ARG1 (0.36) ARG1MALT1
Hydrochloric Acid SCHEMBL20453849 0.80 ARG1 (0.38) ARG1LMNATSHRALDH1A1MEN1
SCHEMBL16771693 0.79 ARG1 (0.38) ARG1MALT1
SCHEMBL16771700 0.79 ARG1 (0.38) ARG1MALT1
SCHEMBL4666386 0.79 ARG1 (0.38) ARG1MALT1
SCHEMBL20663543 0.79 PRCP (0.44) ARG1LMNATSHRSMN1; SMN2EPHX2
SCHEMBL18381289 0.79 PRCP (0.44) ARG1LMNATSHRSMN1; SMN2EPHX2
SCHEMBL19051508 0.78 FDPS (0.44) ARG1LMNATSHRSMN1; SMN2EPHX2
SCHEMBL19051510 0.78 TSHR (0.38) LMNATSHRSMN1; SMN2EPHX2PRCP
Hydrochloric Acid SCHEMBL18259318 0.78 ARG1 (0.38) ARG1MALT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170183318-A1 AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) 2017-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170183318-A1 AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES ACE, ACE2, MCTS1 ARG1 1852/4885LMNA 129/4885TSHR 2783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.